Nanobiotix Prices $98.6 Million Global Offering

Nanobiotix, a biotechnology company focused on physics-based approaches for cancer treatment, has priced its global follow-on offering, generating approximately $98.6 million (€85 million) in gross proceeds. The offering was oversubscribed and consisted of American Depositary Shares (ADSs) in the United States and ordinary shares and pre-funded warrants in Europe and other countries.

The pricing for the U.S. offering was $38.98 per ADS, while the international offering was priced at €33.60 per ordinary share and €33.57 per pre-funded warrant. The price per ordinary share was set at a 14.92% discount to the volume weighted average price on Euronext Paris over the three preceding trading sessions, based on an exchange rate of €1.00 = $1.16.

Jefferies, TD Cowen, and Stifel served as global coordinators and joint bookrunners for the offering, which was priced on May 21, 2026. The company intends to use the net proceeds to fund its research and development activities, particularly for its late-clinical stage pipeline.

The Executive Board of Nanobiotix decided on the issuance of shares and warrants without preferential subscription rights for existing shareholders, as authorized by a shareholder meeting resolution from May 19, 2025. The pre-funded warrants are exercisable until May 26, 2036, and allow holders to subscribe for one ordinary share at a nominal price.